Acomplia
E874318
Acomplia is the brand name for rimonabant, a cannabinoid receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Acomplia canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10610087 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Acomplia Context triple: [rimonabant, hasTradeName, Acomplia]
-
A.
Lamotrek
Lamotrek is a small atoll in the Federated States of Micronesia known for its traditional seafaring culture and navigational expertise.
-
B.
Andexxa
Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
-
C.
Rinvoq
Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Acomplia Target entity description: Acomplia is the brand name for rimonabant, a cannabinoid receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
-
A.
Lamotrek
Lamotrek is a small atoll in the Federated States of Micronesia known for its traditional seafaring culture and navigational expertise.
-
B.
Andexxa
Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
-
C.
Rinvoq
Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
brand name drug
ⓘ
pharmaceutical drug ⓘ |
| adverseEffect |
anxiety
ⓘ
depression ⓘ dizziness ⓘ insomnia ⓘ mood disorders ⓘ nausea ⓘ suicidal ideation ⓘ vomiting ⓘ |
| approvalYear | 2006 ⓘ |
| approvedBy | European Medicines Agency NERFINISHED ⓘ |
| ATCCode | A08AX01 ⓘ |
| chemicalClass | pyrazole derivative ⓘ |
| contraindication |
major depression
ⓘ
ongoing antidepressant treatment ⓘ |
| developedBy | Sanofi-Aventis NERFINISHED ⓘ |
| developedInCountry | France NERFINISHED ⓘ |
| drugClass | cannabinoid receptor antagonist ⓘ |
| effectOnBodyWeight | promotes weight loss ⓘ |
| effectOnLipidProfile | improves HDL cholesterol ⓘ |
| effectOnTriglycerides | reduces triglyceride levels ⓘ |
| eliminationRoute |
feces
ⓘ
urine ⓘ |
| formulation | oral tablet ⓘ |
| hasActiveIngredient | rimonabant ⓘ |
| hasGenericName | rimonabant NERFINISHED ⓘ |
| indication |
obesity
ⓘ
weight management ⓘ |
| intendedUse | adjunct to diet and exercise for weight loss ⓘ |
| legalStatus | withdrawn ⓘ |
| mechanismOfAction |
reduces appetite via endocannabinoid system modulation
ⓘ
selective CB1 receptor antagonist ⓘ |
| metabolism | hepatic ⓘ |
| notApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| pregnancyCategory | not recommended in pregnancy ⓘ |
| regulatoryDecisionInUnitedStates | never approved ⓘ |
| regulatoryStatus | withdrawn from market ⓘ |
| routeOfAdministration | oral ⓘ |
| targets | CB1 receptor NERFINISHED ⓘ |
| therapeuticArea |
metabolic disorders
ⓘ
obesity treatment ⓘ |
| tradeNameOf | rimonabant NERFINISHED ⓘ |
| withdrawalReason |
increased risk of depression
ⓘ
increased risk of suicidal ideation ⓘ psychiatric side effects ⓘ |
| withdrawnBy | European Medicines Agency NERFINISHED ⓘ |
| withdrawnInRegion | European Union NERFINISHED ⓘ |
| withdrawnYear | 2008 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Acomplia Description of subject: Acomplia is the brand name for rimonabant, a cannabinoid receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.